|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 10/14/10 | Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug | RE |
| 09/14/09 | Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
Karen Rogers
PRN | Corporate Officer/Principal | - | - |
| Sales & Marketing | - | - | |
| Corporate Officer/Principal | - | 01/01/1997 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 01/09/2006 | |
| Director/Board Member | 72 | 25/09/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.26% | +6.61% | +40.79% | +145.27% | 1,28600Cr | ||
| +0.79% | +3.45% | +45.84% | +92.04% | 69TCr | ||
| +0.20% | +1.28% | +26.97% | +114.41% | 52TCr | ||
| -0.44% | +3.69% | +41.45% | +70.04% | 39TCr | ||
| +0.55% | +0.70% | +59.02% | +45.79% | 36TCr | ||
| -0.12% | +0.74% | +28.39% | +60.32% | 30TCr | ||
| +0.37% | +0.37% | +3.33% | +38.57% | 29TCr | ||
| -0.30% | +1.14% | +38.29% | +70.56% | 25TCr | ||
| +0.08% | +0.71% | +34.44% | +123.99% | 21TCr | ||
| Average | +0.27% | +2.08% | +35.39% | +84.55% | 48TCr | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.70% | +99.28% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
















